Cells producing neutralizing monoclonal antibodies to a serotype 3 human neonatal rotavirus strain RV-3 were derived by fusion of hyperimmunized mouse spleen cells with mouse myeloma cells. As ascites fluid, three rotavirus-neutralizing monoclonal antibodies were characterized by hemagglutination inhibition and reacted with 17 cultivable mammalian rotaviruses representing five virus serotypes, by fluorescent focus neutralization and enzyme immunoassay. Two antibodies, Mab RV-3:1 and Mab RV-3:2, reacted with the seven serotype 3 rotaviruses only. Mab RV-3:1 was shown to bind to the outer capsid glycoprotein gp34 of rotavirus when variants of SA 11 rotavirus were used, and it therefore appears to react with the major neutralization epitope of serotype 3 rotaviruses. The antibody Mab RV-3:3 was specific for an epitope of RV-3 rotavirus not present on any other rotavirus of any serotype tested, including another neonatal isolate of identical RNA electropherotype isolated from the same ward of the same hospital as RV-3 3 months earlier. These two viruses were also distinguishable by fluorescent focus neutralization, using antiserum to RV-3 virus. Western blot analysis showed binding of Mab RV-3:3 to the trypsin cleavage product of the outer capsid protein p86 of RV-3. This suggests that antigenic drift may have occurred among neonatal rotaviruses in Melbourne. These monoclonal antibodies will be useful in serotyping assays of rotaviruses directly in stool samples, and in further analysis of antigenic variation within the serotype.
A number of authors have reported production of monoclonal antibodies to mammalian rotaviruses (11, 13, 24) . Most of these antibodies were directed to the major inner capsid protein, which bears shared antigenic determinants as well as those involved in subgroup reactions (13) . Recently, strain-specific neutralizing monoclonal antibodies directed at surface proteins of the serotype 3 simian rotaviruses SA 11 (27) and RRV-2 (14) have been described. Two distinct epitopes on the major surface glycoprotein of SA 11 rotavirus which relate to virus neutralization were identified with the neutralizing monoclonal antibodies to SA 11 (28) . However, the production of neutralizing monoclonal antibodies to human rotaviruses has not been reported.
An important application of rotavirus-neutralizing monoclonal antibodies not yet addressed is the serotyping of rotavirus strains directly from stools, by enzyme immunoassay (EIA) or equivalent method. Rotavirus serotyping has been achieved with EIA (29) and solid-phase immune electron microscopy (12) , with carefully cross-absorbed antisera. However, as these antisera are difficult to produce, most serotyping has been by plaque neutralization assays (17, 19, 28, 31) and fluorescent focus neutralization (FFN) assays (3) . These methods usually are suitable only for cultivable rotaviruses, so serotyping has been restricted and progress impeded in cross-protection studies and evaluation trials of candidate human rotavirus vaccines.
In this paper, we describe the production and characterization of neutralizing monoclonal antibodies to the neonatal human serotype 3 rotavirus, RV-3 (1). These antibodies were reacted with a panel of mammalian rotaviruses by EIA and FFN assay. The possible occurrence of antigenic drift suggested by the monoclonal antibody reactions with the virus panel was investigated with polyclonal antiserum, and * Corresponding author. Previously known as Barbara S. McLean. the virus proteins to which the monoclonal antibodies are directed were identified by Western blot analysis and SA 11 rotavirus variants.
MATERIALS AND METHODS
Viruses and cells. Human neonatal rotaviruses RV-1 and RV-3 (serotype 3) and human rotaviruses RV-4 (serotype 1) and RV-5 (serotype 2) were adapted for culture in our laboratory by J. Albert (1). RV-1 and RV-3 were used at passage levels 11 and 13, respectively. Human rotavirus strains YO, S2, and KU were donated by T. Kutsuzawa (31) . MMU18006, rhesus rotavirus strain 2 (RRV-2) was the gift of N. Schmidt, and simian rotavirus SAl was kindly supplied by H. Malherbe (San Antonio, Tex.). Canine rotavirus LSU-79C36 (K9; 10) was provided by G. Woode, who, with J. Bridger, isolated the UK strain of bovine rotavirus provided by T. Flewett (33) . Human rotavirus strains Wa, DS-1, P, and ST-3 were kindly donated by R. G. Wyatt.
All viruses were propagated in MA104 cells in the presence of trypsin, as previously described (25) .
The myeloma cell line P3-X63-Ag8-653 (clone 653) used for fusion is an azaguanine-resistant derivative of a nonsecreting line of myeloma cell clones (18) . The cells were cultured as described previously (6) in Dulbecco modified Eagle medium (DMM) with 20% (vol/vol) heat-inactivated fetal calf serum.
Immunization. BALB/c mice 8 weeks old were immunized with intact, double-shelled RV-3 rotavirus particles, which were prepared by fluorocarbon extraction and banding in cesium chloride gradients as previously described (23) . Throughout the virus purification procedure, Tris-buffered saline (pH 7.2) with 10 mM calcium chloride was used to stabilize the outer capsid layer (5) . Mice were immunized intraperitoneally with 0.4 ml of virus in Fruend complete adjuvant, and two mice were boosted 2 months later by the same route with 0.1 ml of virus in Freund incomplete NEUTRALIZING MONOCLONAL ANTIBODIES TO HUMAN ROTAVIRUS adjuvant, as well as with 0.2 ml of virus by the intravenous route. Three days later, one mouse (A) was sacrificed and its spleen was removed for fusion. The second mouse (B) received a further intravenous boost 2 months after its first boost and was sacrificed for splenic fusion 3 days later. Both mice showed preinoculation anti-RV-3 EIA titers of 1:50 in serum. After the first booster injection, their EIA titers rose to 1:160,000, with RRV-2 hemagglutination inhibition (HI) titers of greater than 1:2,000 and RV-3 FFN titers of 1:50,000.
Production of hybridoma cell lines. The methodology for production of hybridoma cell lines has been described elsewhere (6) . Spleen cells from hyperimmunized mice were fused with clone 653 myeloma cells, using polyethylene glycol. Parental myeloma cells were killed by medium containing 100 ,uM hypoxanthine, 4 nM aminopterin, and 16 ,uM thymidine. Fused cells were distributed into 96-well (0.2-ml) Linbro plates. The culture fluids were tested for antibody production by EIA, HI, and FFN. Hybridomas that showed HI and FFN activity were subcloned at least twice by limiting dilution and grown in syngeneic mice primed with Pristane (ICN Pharmaceuticals, Plainview, N.J. as ascites.
EIA for rotavirus antibodies. THE EIA was performed as described previously (21) . Hybrid culture fluids were tested at a dilution of 1 in 5 in phosphate-buffered saline (PBS) (pH 7.2) containing 1% (wt/vol) bovine serum albumin (PBS-B) in polyvinyl microtiter plates (Dynatech Laboratories, Inc., Alexandria, Va.) coated with optimal dilutions of RV-3 (serotype 3), RV-5 (serotype 2), and SA 11 virus antigen and MA104 cell control antigen. These EIA antigens were produced by fluorocarbon extraction and ultracentrifugation of virus-infected or uninfected cell harvests as described previously (5, 23) . Bound antibody was detected with goat antimouse immunoglobulins conjugated to horseradish peroxidase (DAKO Immunoglobulins, Copenhagen, Denmark) and orthophenylene diamine (Sigma Chemical Co., St. Louis, Mo.) as substrate (32) . The absorbance of each well at 492 nm was recorded with a Titertek Multiskan spectrophotometer (Flow Laboratories, Inc., Rockville, Md.). Optimal dilutions of reagents were determined by checkerboard titration.
Ascites fluids and affinity-purified monoclonal antibodies were titrated by EIA, using doubling dilutions of monoclonal antibody. Wells were coated with any of the rotaviruses as described above, and MA104 control antigen, at optimal dilution.
HI assay for rotavirus antibodies. Viral hemagglutinins used for the HI assay were prepared by freezing and thawing rotavirus-infected MA104 cells showing complete cytopathic effect. This virus preparation was stored in aliquots at -70°C. All hybridoma cultures were screened for inhibition of RRV-2 hemagglutination (HA), using PBS-B throughout as diluent. An aliquot (25 p.1) of hybrid culture fluid diluted 1 in 5 was incubated at 37°C with an equal volume of HA antigen-containing 4 HA units in U-bottomed microtiter trays. After 1 h, 50 pt1 of 0.5% human group 0 erythrocytes was added, and results were recorded after further incubation for 1 h at 37°C. Antigen, cell, and positive and negative hybridoma supernatants and sera were included in each test.
Rotavirus HI antibodies in ascites fluids were titrated in duplicate, using serial twofold dilutions. The HI titers were expressed as the reciprocal of the highest dilution of monoclonal antibody showing complete inhibition of HA. FFN 30 min, the plates were incubated at 37°C in an atmosphere of 5% CO2 and 95% relative humidity overnight and stained by indirect immunofluorescence.
The dilution of rotavirus RV-3 (serotype 3) giving 100 fluorescent cell-forming units was determined previously by inoculation of MA104 cell monolayers with doubling dilutions of virus in DMM-T, followed by centrifugation, incubation, and staining as described above.
As virus controls, DMM-T and clone 653 supernatant fluid were included. Incubation of clone 653 supernatant alone with RV-3 was found to give a 10% reduction in fluorescent cell count. However, neutralizing hybridoma supernatants reduced the number of fluorescing cells at least 10-fold.
Mouse ascites fluids were titered for neutralizing antibody by using fourfold dilutions of ascites mixed with an equal volume of any of the rotaviruses described above, diluted to give ca. 100 fluorescent cell-forming units per well. The neutralization titer of each fluid was expressed as the reciprocal of the highest dilution giving 50% reduction in the number of fluorescing cells.
Indirect immunofluorescence. Rotavirus-infected cells were fixed in acetone for 5 min and air dried. Rabbit hyperimmune antiserum to SA 11 (50 RI) at optimal dilution (1:500) in PBS was added to each well, and the plates were incubated for 1 h at 37°C. The plates were washed three times with PBS before the addition to each well of 25 ,u of fluorescein isothiocyanate-labeled goat antirabbit immunoglobulin G (IgG) (TAGO Inc.) diluted 1:50 in PBS. After a further 1-h incubation at 37°C, the plates were washed again and air dried. The inverted wells were observed with a Zeiss epifluorescent UV microscope (magnification, x80). Specific fluorescence appeared only in the cytoplasm of infected cells; uninfected cells showed no specific fluorescence.
Plaque neutralization assay. The plaque neutralization assay method of Matsuno et al. (19) , modified by Smith et al. (26) , was adopted for use with RRV-2 virus by the addition of 50 p.g of DEAE-dextran per ml (Pharmacia Fine Chemicals, Inc., Piscataway, N.J.) to the first agarose overlay. Hybridoma culture supernatants were screened at a dilution of 1 in 4.
Polyacrylamide gel electrophoresis of double-stranded RNA of rotavirus. Electropherotyping of viral RNA was performed on all stocks of rotavirus strains studied (see Tables  4 and 5 ). Viral RNA was prepared by phenol-chloroform extraction (8) . Polyacrylamide gel electrophoresis of viral RNA was performed with the Laemmli buffer system (26) at 15 mA for 18 h at 4°C. The RNA was visualized with silver stain (8) .
Western blot analysis. Partially purified rotavirus particles, prepared by fluorocarbon extraction and ultracentrifugation of infected cell harvests (5, 23) , were solubilized in sample buffer and electrophoresed in 9% polyacrylamide-Laemmli gels (26) at 25 mA until the dye front reached 1 cm from the end of the gel. To obtain fully reduced proteins, samples were boiled in sample buffer containing 5% 2-mercaptoethanol and 2% sodium dodecyl sulfate (SDS) and were run in a gel containing SDS. For unreduced proteins, samples were heated to 60°C for 5 min in sample buffer without 2-mercaptoethanol and applied to a gel prepared without SDS. All VOL. 54, 1985 bTiter of mouse ascites fluid. Titers of the three monoclonal antibodies against human serotype 1 strains (Wa, KU, RV-4), human serotype 2 strains (DS-1, S2, RV-5), the human serotype 4 strain ST-3, and the UK bovine strain were all <100. Serotyping of RV-1, RV-3, and RV-4 was performed by FFN, using hyperimmune sera to Wa and SA 11 rotaviruses prepared as previously described (2) and Wa and SA 11 rotaviruses as controls. The serotype of RV-5 was determined by Dyall-Smith and Holmes (8) . Serotyping of the remaining strains has been described previously (34) .
As others have found (11, 13, 24, 27) , the majority (95%) of rotavirus antibodies appeared to be cross-reactive between rotavirus strains. A further 1.6% of antibodies were specific for the serotype 3 rotaviruses tested (RV-3 and SA 11) but were nonneutralizing. The remaining 3.4% of antibodies neutralized RV-3. With increased spleen cell numbers, fusion 101 produced an increased yield of both EIA-positive and neutralizing antibody-producing hybrids. However, fewer than 50% of the latter hybrids survived beyond two subculture steps. The three surviving neutralizing clones fell into two groups: two appeared to be specific for serotype 3 viruses and inhibited HA; one reacted with homologous virus only and did not inhibit HA. These monoclones form the basis of the studies reported here. Their detailed characterization by EIA, FFN, and HI is See footnote a to Table 3 .
Titers of the three monoclonal antibodies against human serotype 1 strains (Wa, KU, RV-4), human serotype 2 strains (DS-1, S2, RV-5), the human serotype 4 strain ST-3, and the UK bovine strain were all s400. The serotyping of these rotaviruses was described previously. See footnote b to Table 3 . ' As mouse ascites fluid. (Fig. 3) . No binding of Mab RV-3:3 to unreduced SA 11 virus proteins was observed. The locations of the unreduced RV-3 virus proteins corresponding to gp34 of SA 11 (the neutralization antigen) and the major group antigen p42 (2, 14) are shown in lanes F and G of Fig. 3 with monoclonal antibodies C4/B3 and 4C8, which have been shown to immunoprecipitate gp34 and p42 of SA 11 virus, respectively (28) . The Mab RV-3:3 therefore reacted with a protein unrelated to these rotaviral antigens. Comparison of the reduced RV-3 proteins detected by the use of anti-RV-3 serum (Fig. 3, lane A) with molecular weight standards allowed identification of the RV-3 virus proteins, by analogy with SA 11 rotavirus (2). Polypeptides 111, 98, 94, and 86 of RV-3 correspond to polypeptides 113, 96, 91, and 84 of SA 11. The molecular weights of p42 and gp34 did not vary between the two rotaviruses when reduced proteins were studied. The presence of the RV-3 virus protein p62, corresponding to p62 of SA 11 virus, the trypsin cleavage product of the outer capsid protein p84 (2) or VP3 (9), was notable. This protein, of the same molecular weight, was also de- these aggregates in favor of the p42 band in the presence of 2-mercaptoethanol suggests that the polymeric forms of p42 are linked via disulfide bonds, as previously postulated (2).
Binding of Mab RV-3:1 and Mab RV-3:2 under reducing or nonreducing conditions to RV-3 or SA 11 rotaviruses in Western blots could not be demonstrated, so variant analysis was attempted. Variants of wild-type (wt) SA 11 rotavirus, selected with the SA 11-neutralizing monoclonal antibody A1OIN3, which immunoprecipitates gp34 (28), were tested for their ability to be neutralized by Mab RV-3:1 and Mab RV-3:2. The FFN titers are shown in Table 5 , together with titers to wt SA 11 rotavirus and A10/N3 (S. Sonza, personal communication). The Mab RV-3:1 showed a fourlog reduction in neutralization titer with the SA 11 variants, which was comparable to that of AION3. Therefore, the change in gp34 elicited by A1O/N3 has prevented binding of Mab RV-3:1 to the SA 11 rotavirus variants, and so Mab RV-3:1 reacts with an antigen on gp34. The Mab RV-3:2 did not show significantly different neutralization of the variants than wt SA 11 rotavirus, suggesting that if it binds to gp34, it is to a site unaffected by the change in gp34 elicited by A1ON3. (11, 13, 14, 24, 27, 28) . However, we believe this to be the first description of the derivation of neutralizing monoclonal antibodies to a human rotavirus. One problem we encountered was that less than 4% of rotavirus antibody-secreting hybridomas were producing neutralizing antibodies to rotavirus. The instability (5) and inefficient production (25) of intact human rotavirus particles in cell culture may contribute to the low numbers of neutralizing monoclonal antibodies we derived to RV-3 (serotype 3) rotavirus, compared with neutralizing antibody numbers derived to animal viruses which grow well in cell culture, such as SA 11 (28) (14) , but these antibodies also inhibited HA. As monoclonal antibodies directed to gp38, the serotype-related glycoprotein of RRV-2, also neutralized RRV-2 and inhibited its HA, it was not possible to conclude whether the neutralizing activity of the viral hemagglutinin-precipitating antibodies was related to epitopes on the viral hemagglutinin, or to steric hindrance of gp38 epitopes. Similarly, SA 11 virus-neutralizing monoclonal antibodies have been shown also to inhibit HA (28) . Our studies with Mab RV-3:3, which did not inhibit HA by RRV-2, SA 11, or K9, suggest that p86 does contain at least one potential neutralization epitope. This site may be absent on the uncleaved protein, but it is present on the larger trypsin cleavage product (p62) of RV-3 rotavirus and so may be involved in determination of other functions of the protein such as host cell tropism and trypsin-enhanced plaque formation (17) , rather than in viral HA.
The virtual absence of reaction of Mab RV-3:3 with RV-1 (serotype 3) rotavirus, isolated from the same ward of the same hospital as RV-3 (serotype 3) virus and of identical electropherotype, was surprising. The only difference previously noted between RV-1 and RV-3 rotaviruses is that RV-1 does not produce plaques in cell culture, whereas RV-3-infected cell cultures show thickened areas (1), similar to a bovine temperature-sensitive mutant found previously. Again, this suggests that the viral epitope detected by Mab RV-3:3 may relate to trypsin-enhanced plaque formation, and also that this site is subject to a form of antigenic drift. This latter conclusion is reinforced by the higher FFN titer of polyclonal anti-RV-3 hyperimmune serum found with RV-3 rotavirus than with RV-1 rotavirus, which suggests that an immunologically significant difference, not necessarily restricted to the difference detected with Mab RV-3:3, exists between RV-1 and RV-3 rotaviruses. This variation may prove analagous to the antigenic drift of the influenza virus hemagglutinin (35) , or to the variation within poliovirus serotypes generated by selective pressure of antibody (7) . The antigenicity (measured by virus neutralization) of bovine rotavirus strain Reims 18/77 was shown recently to alter drastically after 15 passages in cell culture in the presence of specific antibody (15) . Virus adapted to culture without antibody showed unaltered neutralization kinetics. This may represent experimentally the endemicity of rotavirus strains such as RV-1 and RV-3 in nurseries of maternity hospitals in Melbourne, where for a number of years neonates receiving rotavirus antibody either in breast milk or across the placenta or both have been infected with mild or no symptoms (20) . We plan further analysis of neonatal rotavirus strains, using Mab RV-3:3 and other monoclonal antibodies to investigate this phenomenon.
